Alnylam initiated with a Buy at Guggenheim. Guggenheim analyst Whitney Ijem started Alnylam Pharmaceuticals with a Buy rating and $105 price target. The analyst expects the Onpattro launch will go well given the existing pool of identified patients and the drugs’s profile versus competitors. Second generation vutrisiran will likely further solidify Alnylam’s competitive positioning and expand the market opportunity, Ijem tells investors in a research note.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.